and have identified Rpt3/Rpt5 as 2 subunits vulnerable to oxidative carbonylation in both human end-stage heart failure and experimental myocardial ischemia. 13, 15 Oxidation of Rpt subunits is associated with loss of ATPase activity. 16 In addition, perturbations in protein kinase A-related and calcium/calmodulin-dependent protein kinase II-related signaling pathways in heart failure have been described. 17, 18 Both of these kinases have been shown to phosphorylate several subunits of the 20S usually resulting in increased activity. [19] [20] [21] On the basis of these studies, we propose that the UPS dysfunction associated with end-stage heart failure is because of diminished ATPase activity of the Rpt subunits and altered phosphorylation of the 20S subunits leading to diminished docking or association of 19S regulatory particles with 20S proteasomes.
Methods

Subjects
Human Heart Tissue Procurement
Ventricular myocardial tissue from patients with advanced heart failure at the University of Michigan was collected at the time of cardiac transplantation. Nonfailing ventricular myocardial tissue was collected from unmatched donors from the University of Michigan and other regional hospitals through a protocol with the Gift of Life Michigan Organ and Tissue Donation Program. This project was approved by the University of Michigan Institutional Review Board (IRB) and subjects gave informed consent. Each heart was perfused with ice-cold cardioplegia, samples were snap frozen in liquid N 2 and stored at −80°C. Patient demographics were recorded at the time of tissue collection.
Laboratory
Preparation of Enriched Proteasome Fraction
Enriched proteasome fraction was prepared as described by Gomes et al 19 using differential ultracentrifugation. This procedure typically results in the formation of a proteasome-containing fraction that is >200-fold concentrated (additional detail in the online-only Data Supplement).
15
Native Gel Electrophoresis
Enriched proteasome fraction was subjected to nondenaturing native gel electrophoresis as described by Gomes et al 19 using a 4% polyacrylamide gel. After electrotransference, membranes were probed with polyclonal anti-β5 or anti-Rpt5 (Enzo Life Sciences, Plymouth Meeting, PA) to assess the presence of 20S or 19S, respectively. Immunoprecipitation (additional detail in the online-only Data Supplement). 19S Rpt subunits were immunoprecipitated (IP) with monoclonal anti-Rpt6 antibody (p45-110) (Enzo Life Sciences) as previously described. 15 This antibody precipitates noncomplexed Rpt6 subunits and any Rpt subunits complexed with Rpt6. The antibody:antigen complex was captured using Mouse TrueBlot IgG IP beads (eBioscience, San Diego, CA).
ATPase Activity
Enriched proteasome fraction and IP Rpt subunits were analyzed for ATPase activity using the SensoLyte MG Phosphate Assay Kit (Anaspec, Fremont, CA) according to the kit instructions. Measurements were recorded during the 3-to 30-minute interval in the enriched fraction and in the 2-to 20-minute interval in the IP fractions to allow for completion of nonspecific formation of PO 4 . All results are expressed as ρmol PO 4 /μg protein per hour (additional details in the online-only Data Supplement).
Phosphopeptide Analysis of Enriched Proteasome Fraction
Briefly, samples were quantitated using the Qubit fluorescence platform (Invitrogen, Carlsbad, CA) with nano liquid chromatography/ mass spectrometry/mass spectrometry (Waters NanoAcquity HPLC system, Milford, MA) interfaced to a Thermo Fisher LTQ Orbitrap Velos (Waltham, MA). The 15 most abundant ions were selected for mass spectrometry/mass spectrometry. Data were searched using a local copy of Mascot. Mascot DAT files were parsed into the Scaffold software for validation, filtering, and to create nonredundancy across all samples. Data were filtered using a minimum protein value of 90%, a minimum peptide value of 50% (Prophet scores), and requiring at least 2 unique peptides per protein (in-depth protocol in the online-only Data Supplement).
Statistics
Differences between nonfailing and failing hearts were determined using Fisher exact test for dichotomous variables or a Mann-Whitney rank-sum test for continuous variables (SigmaStat; Jandel Scientific, San Rafael, CA), with P≤0.05 considered to be significant. All values are expressed as the mean±SEM.
Results
Characteristics of End-Stage Heart Failure Patients
The demographics of patients from whom heart tissue samples were obtained are described in the Table. Age and race were not significantly different between nonfailing and failing groups. A greater proportion of the donor hearts was from women compared with failing hearts (P=0.05). The failing samples were selected so as to minimize patients with left ventricular assist devices as proteasome activity is enhanced with mechanical unloading. 13 As we are not aware of any studies that show a sex bias in proteasome function in either failing or nonfailing hearts, we think it unlikely that this sex discrepancy would affect interpretation of the results. As expected, systolic function (as measured by echocardiography) was markedly lower in failing compared with nonfailing hearts.
Docking of 19S to 20S is Decreased in End-Stage Human Heart Failure
To evaluate docking of 19S to 20S, enriched proteasome fraction was subjected to native gel electrophoresis. Membranes were probed with antibodies to the β5 or Rpt5 subunits to detect presence of 20S or 19S, respectively. High molecular weight bands were deemed to contain docked 26S or 30S if recognized by both antibodies. In general, 3 proteasome populations were detected: 20S (not docked), 26S (20S docked with 1 19S), and 30S (20S docked with 2 19S; Figure 1A ). Overall docking, defined as the amount of 19S associated with 20S and included both 26S and 30S, was lower by almost 30% (P=0.073) in failing hearts with docking of 30S significantly lower by 37% (P=0.048; Figure 1B ). Total 20S was lower by ≈20% but this was not significant. Decreased docking was not associated with significant differences between failing and nonfailing hearts in the protein abundance of any 20S or 19S subunits as detected by mass spectrometry (Table I in the online-only Data Supplement).
Rpt Subunit ATPase Activity is Lower in End-Stage Human Heart Failure
To determine function of the Rpt subunits in the base of the 19S, ATPase activity of the enriched proteasome fraction was determined and found to be lower by 34% (Figure 2A ). Because the enriched fraction contains many other proteins, 15 some of which may have ATPase activity, the Rpt subunits were IP with an anti-Rpt6 antibody. Because the immunoprecipitation was not performed under denaturing conditions, any Rpt subunits in complex with Rpt6 would coimmunoprecipitate. Immunoblotting of the IP material confirmed the presence of other subunits, such as Rpt5, besides Rpt6 ( Figure 2B ). ATPase activity of the IP material was less than that of the enriched fraction and was significantly lower (P=0.005) by >90% in the failing hearts ( Figure 2A ). In several of the IP samples from failing hearts, ATPase activity was not detectable.
Phosphorylation of the α7 Subunit of the 20S is Lower in End-Stage Human Heart Failure
Phosphorylation of 20S subunits is likely necessary for docking of 19S to 20S proteasomes. Enriched proteasome fraction Lower docking of the 19S regulatory particle to the 20S proteasome in end-stage human heart failure. Enriched proteasome fraction from nonfailing and failing human hearts was subjected to native gel electrophoresis. A, After transference, membranes were probed with an antibody specific for the β5 subunit to identify bands containing the 20S proteasome (left), or with an antibody specific for the Rpt5 subunit to identify bands containing the 19S regulatory particle (right). B, Undocked 20S was estimated by densitometry of the lower band recognized by the β5 antibody (top left). Total docked proteasome (26S or 30S) was estimated by densitometry of all bands recognized by the Rpt5 antibody (top right); 26S (bottom left) or 30S (bottom right) was estimated by densitometry of the upper (30S) or lower (26S) bands recognized by the Rpt5 antibody. The values are graphed in a dot plot, with lines representing the mean value for each group; n=5 (nonfailing) and n=7 (failing) hearts. Enriched proteasome fraction from both nonfailing and failing hearts was immunoprecipitated with anti-Rpt6 under nondenaturing conditions. The antigen:antibody complex was captured using the Mouse TrueBlot IgG beads. Equivalent volumes of the beads and the resultant supernatant were then subjected to polyacrylamide gel electrophoresis under denaturing conditions. The blot was then probed with an antibody to Rpt5. Heavy-chain contamination is ruled out by the blank (BL) which in this case was enriched fraction buffer (no protein) treated in a like manner with the Rpt6 antibody and the beads.
was subjected to mass spectrometry phosphopeptide mapping to assess phosphorylation of 20S subunits. Phosphorylation of the α7 subunit at serine 250 was detectable with a reliable signal in all samples. The relative percentage of phosphorylated protein (expressed as a total of phosphorylated+nonphosphor ylated) was significantly lower (P=0.011) in failing compared with nonfailing hearts ( Figure 3A) . Chromatographic peak areas for phosphorylated and nonphosphorylated α7 for all hearts examined are presented in Table II in the online-only Data Supplement. Casein kinase II is the only kinase reported to phosphorylate α7 at serine 250. 22 However, casein kinase II expression was actually higher by almost 70% (P=0.019) in the failing hearts ( Figure 3B and C) . Phosphorylated peptides were detected for Rpt6, Rpn6, and Rpn1 in some of the samples, but signals were too low for accurate quantification.
Discussion
Several studies have either directly 13 or indirectly 23, 24 shown that the UPS is dysfunctional in human end-stage heart failure. This is unlike autophagy, which seems to be activated in both experimental models 25 and in human end-stage heart failure 26 perhaps to maintain protein quality control. On the basis of previous studies in experimental myocardial ischemia models suggesting preferential effects on the ATP-dependent activities of the proteasome, 14 we theorized that a persistent defect must be present in the 19S regulatory particle. We have shown that at least 1 of the Rpt subunits is vulnerable to oxidative damage in both experimental myocardial ischemia 15 and in human end-stage heart failure. 13 Proper function of the UPS requires docking of a 20S proteasome with 1 or 2 19S regulatory particles, which is dependent on ATPase activity of the Rpt subunits in the 19S, and likely phosphorylation of 20S subunits. [7] [8] [9] In the present study, we show that UPS dysfunction in human end-stage heart failure is associated with diminished docking of the 19S to 20S, loss of ATPase activity of the Rpt subunits found in the base of the 19S, and decreased phosphorylation of the α7 subunit, the most heavily phosphorylated subunit of the 20S proteasome.
Diminished docking of the 19S to 20S has not been described previously in end-stage heart failure. The only study to examine docking in a cardiac pathology associated with UPS dysfunction does suggest that it can be diminished; however, this was in response to myocardial ischemia. 27 Nonetheless, the results do indicate that there was less 19S associated with 20S. There are 2 main determinants of proper docking, the ATPase activity of the Rpt subunits within the base of the 19S and signaling events that alter phosphorylation of proteasome 19S and 20S subunits. The most recent studies all suggest that proper function of the Rpt subunits is critical for assembly of complete 26S (or 30S) proteasomes. 28, 29 The current thinking is that on ATP binding, the C termini of the Rpt subunits interact with pockets between the 20S α subunits fostering docking of the 19S with a 20S and also opening the access gate and stimulating hydrolysis of peptides. 28, 29 The 2 most important Rpt subunits for this function seem to be Rpt2 and Rpt5, the latter being 1 of the subunits previously observed to be oxidized in human end-stage heart failure and experimental myocardial ischemia. 13, 15 In general, ATPases have been observed to be sensitive to oxidative inactivation 30 ;
thus, it is plausible that the diminished Rpt ATPase activity in failing heart is related to oxidative damage, consistent with a previous report in an in vitro cellular preparation exposed to an oxidizing environment. 16 The other determinant of docking is phosphorylation of 19S and 20S subunits. Several subunits have been observed to be phosphorylated, including α2, α3, α5, α7, β1, β2, β3, β5, β6, and β7 on the 20S 9,20,22 and Rpt6 31,32 on the 19S. In general, phosphorylation of proteasome subunits tends to stabilize the proteasome and increase activity. 9, 20 Phosphorylation of Rpt6, in particular, seems to enhance docking and stabilize the 26S (or 30S) proteasome. 31, 32 One of our primary observations is that phosphorylation of the α7 subunit at serine 250 , the major of the 2 known phosphorylation sites, is lower. Diminished phosphorylation of this subunit would be consistent with the observed decreased docking and reported diminished activity of the UPS in end-stage heart failure. 13, 23, 24 Several kinases have been reported to phosphorylate various subunits of the 26S proteasome, including protein kinase A, calcium/calmodulindependent protein kinase II, and casein kinase II. 9, [19] [20] [21] [22] In fact, it is likely that phosphorylation of multiple subunits by protein kinase A accounts for its ability to enhance assembly of 26S Figure 3 . Proteomic profiling and casein kinase II (CKII) expression in cardiac proteasomes from human donor and failing hearts. A, Dot plot graphic summary of percentage phosphorylation of the α7 C-terminal tryptic peptide. The lines represent the mean value for each group. The liquid chromatography/mass spectrometry high-resolution accurate mass peak areas for both the ESLKEEDESDDDNM and ESLKEEDEpSDDDNM peptides (oxidized and nonoxidized methionine versions of each) were manually calculated in each sample, and across multiple gel bands per sample. PO 4 α7 was expressed as a % of total α7. Although it is valid to compare these ratios between samples, they may not reflect absolute stoichiometry of the PO 4 and non-PO 4 α7 peptides, due to potential differences in response factors, that is, different behaviors of the 2 peptides by electrospray ionization; n= 4 (normal) and n=6 (failing) hearts. B, Representative Western blots showing CKII expression with GAPDH used to normalize protein loading. C, Graph summary of mean CKII expression for control and failing human hearts; n=5 (control) and n=8 (failing) hearts.
proteasome in canine heart. 27 However, only casein kinase II is known to phosphorylate the α7 subunit at serine 250 , and thus was a reasonable prospect for analysis. 22 Yet, we observe that like other kinases, casein kinase II is increased in human end-stage heart failure, and thus is contrary to the finding of decreased phosphorylation at this site. One possible explanation is increased phosphatase activity. Both PP1 and PP2A have been shown to dephosphorylate several proteasome subunits and in general decrease proteasome activity 20 ; although, at this time it is not apparent which of these dephosphorylates serine 250 of α7. In studies of human heart failure, upregulation of PP1 33, 34 and increased phosphatase activity attributed to PP1 and PP2A have been consistently documented.
34-37 Therefore, we hypothesize that increased phosphatase activity is responsible for relative dephosphorylation of serine 250 of α7 observed in human end-stage heart failure compared with control hearts.
Limitations
The major limitation of any study using human samples is inherent variability in disease pathology, medical therapy, and availability and suitability of matched control heart tissue. By necessity, we are limited to a single time point, that is, explants from failing hearts at time of transplantation, thus the results of this study are applicable to end-stage heart failure only. In addition, the use of interventions to show cause and effect is limited and unfortunately, apical core samples obtained at time of left ventricular assist device do not provide enough tissue to prepare the enriched proteasome fractions. Several previous studies [38] [39] [40] in experimental animal and cellular models have observed either increased UPS activity during development of hypertrophy and failure or have suggested that inhibition of the proteasome might be of clinical value. There is controversy as at least 1 study was unable to reproduce these results and observed the opposite. 41 Because the current study was conducted on explanted end-stage failing hearts, it has little bearing on these previous studies, which examined relatively early events in the development of heart failure in short-term animal experimental models. All the previous studies in human heart, suggesting that the UPS is dysfunctional, were done on explanted end-stage failing hearts, thus the observations are relevant to this clinical phase only, which is difficult to model in experimental animals. 13, 23, 24 A limitation of the proteomics studies is that only the most heavily phosphorylated subunit, α7, was detectable at a threshold sufficient to warrant quantitative comparison between groups. Therefore, we cannot exclude the possibility that there are biologically relevant differences in the phosphorylation of other proteasome subunits between nonfailing and failing hearts.
Summary and Clinical Relevance
This study examines the molecular basis for dysfunction of the UPS in end-stage heart failure. We observed decreased docking of the 19S to the 20S which could account for the previously reported decrease in proteasome activity in endstage heart failure. We propose that the diminished docking is related to the observed loss of 19S Rpt subunit ATPase activity and decreased phosphorylation of the most heavily phosphorylated α subunit of the 20S. From a clinical perspective, a more thorough understanding of the mechanisms that underlie UPS dysfunction could lead to development of interventions that either prevent the oxidative damage that leads to loss of ATPase activity or augmentation of subunit phosphorylation by alteration of either kinase or phosphatase activities.
This study examined a potential mechanism for loss of proteasome function in human end-stage heart failure. The proteasome is a very large complex that has as 1 of its functions maintenance of protein quality control within the heart. In order for proteasome to accomplish this efficiently, this large complex must assemble completely and in proper order. We show that in human end-stage heart failure, a component that regulates the function of the proteasome does not combine efficiently with the main complex. We identify 2 potential mechanisms as to why this occurs with the thought that a more thorough understanding of these mechanisms could lead to interventions that could conceivably improve cardiomyocyte function in the failing heart.
CLInICAL PERSPECTIvE
